Peter Kolchinsky, Ph.D. ‘01

Co-founder, Portfolio Manager, & Managing Director, RA Capital Management

Peter Kolchinsky (Ph.D ’01) is co-founder, Managing Director, and Portfolio Manager of RA Capital Management, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life science companies. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves as a member of the Board of Directors for a number of private companies. He is the author of “The Entrepreneur’s Guide to a Biotech Start-up” and the Biotech Social Contract series.


Chandra Ramanathan, PhD, MBA.

Vice President and Head of the East Coast Innovation Center at Bayer & Board of Director at MassBio

Chandra Ramanathan is Vice President and Head of East Coast Innovation Center at Bayer. He is responsible for establishing the East Coast Innovation Center, building an innovative product portfolio with key academic partners, driving external scientific leadership and engaging with members of the local innovation ecosystem.  Chandra is also on the Board of Director at MassBio. He holds an M.B.A from the Columbia Business School, Ph.D. in Genomics/Bioinformatics, M.S. in Medicinal Chemistry and B.S. in Pharmacy. 


john.png

John Maraganore, PhD.

Chief Executive Officer and Director of Alnylam.

John is Chief Executive Officer and Director of Alnylam. Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory, and metabolic diseases. Before Millennium he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, formerly HIRULOGTM and currently marketed by The Medicines Company. Dr. Maraganore received his MS and PhD in biochemistry and molecular biology at the University of Chicago. He is the Chair of the Board for Agios Pharmaceuticals. Dr. Maraganore is a member of the Biotechnology Industry Organization (BIO) Board and former BIO Chair.

Pearl Freier

President, Cambridge BioPartners

Pearl Freier is President of Cambridge BioPartners, Inc., a strategic advisory firm specializing in targeted search and business development services for the biopharmaceutical and healthcare technology industries. The firm’s methodologies have been used as best practices for several industry groups throughout North America over the years. Pearl has been quoted in publications including BIO-IT World, The Boston Globe, Nature, The Philadelphia Inquirer and Science and has served the biopharmaceutical and healthcare technology industries for over 10 years.